A phase 1/2 study to evaluate the combination of TG4001 with Avelumab in patients with HPV-Positive head & neck cancers
Phase of Trial: Phase I/II
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Avelumab (Primary) ; Tipapkinogene sovacivec (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 20 Mar 2017 According to a Transgene media release, first patient enrollment expected in 2H 2017. Prof. Christophe Le Tourneau will be principal investigator of this study.
- 26 Oct 2016 New trial record
- 20 Oct 2016 According to a Transgene media release, this study is expected to start in the first half of 2017.